Base editing strategies for in vivo correction of two highly recurrent phenylketonuria variants
Brief intro:
- Author: Aidan Quigley, Ishaan Jindal, Thomas Campion, Delaney Rutherford, Yongseok Han, Walsh Quigley, Ping Qu, Kiran Musunuru, Rebecca Ahrens-Nicklas, Xinying Hong, Xiao Wang
- Journal: Molecular Therapy
- Doi: https://www.doi.org/10.1016/j.omtn.2025.102770
- Publication Date: 2025/12/9
Abstract
Phenylketonuria (PKU) is an autosomal recessive disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene. Previously, we have shown correction of the most recurrent PKU variant using both base editing and prime editing. In this work, we set out to screen base editors and single guide RNAs (sgRNAs) in vitro to identify sgRNA-editor combinations that would provide sufficient correction for phenotypic rescue of the next four most recurrent PKU variants. For three candidates, we established efficient corrective editing in vitro. We then assessed the off-target editing profile of each sgRNA-editor combination. For two of these variants, we demonstrated efficient corrective editing in the livers of humanized mouse models via adeno-associated viral (AAV) delivery. This work identifies base editing strategies for in vivo correction of the second and third most common pathogenic variants of PKU.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.